Alzamend Neuro is trading at $1.22, up 5.2% today, as the stock rebounds from recent selling pressure driven by geopolitical tensions and sector-wide profit-taking.
- The stock had previously been weighed down by risk-off sentiment tied to U.S.–Iran tensions and broader weakness in high-beta biotech names.
- Today’s move appears to reflect a partial recovery as growth stocks rally following the release of softer inflation data.
- There are no new company-specific news or fundamental catalysts reported for the stock as of July 14, 2026.